rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Efficacy of Transversus Abdominis Plane Block
Status: Recruiting

This study aims to assess the efficacy of Transversus Abdominus Plane (TAP) blocks, a well-established anesthetic technique, to decrease the amount of post-operative pain in patients who undergo minimally invasive gynecologic surgeries. During minimally invasive gynecologic surgeries, the abdomen is inflated with pressurized air for visualization purposes and released at the end of the surgery. Traditionally, TAP blocks are performed by injecting long-acting local anesthetic agents under ultrasound guidance into the abdominal wall after abdominal surgery after the air has been emptied from the abdomen for additional anesthetic coverage post-operatively. This study proposes a novel approach: that performing TAP blocks while the abdomen is still insufflated will result in better post-operative pain outcomes as compared to the traditional method.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Female gynecological patients between 18 years and 85 years consented and scheduled for an obstetrics/gynecology laparoscopic procedure. Consent received to receive a TAP block.  Exclusion Criteria:  Patients who are not proficient in the English language or cannot consent Patients who have an allergy to local anesthetics (amides) Patients with subcutaneous emphysema Patients whose surgical procedures require incisions above the umbilicus - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC
Status: Not yet recruiting

The goal of this clinical trial is to compare induction treatment with CT-P13 SC to induction treatment with CT-P13 IV in terms of pharmacokinetics in adult patients with inflammatory bowel disease (IBD) who have been diagnosed for at least 3 months and for whom the physician has decided to initiate treatment with infliximab CT-P13 as part of the standard of care.

The main aim of this study is to demonstrate that induction treatment with CT-P13 SC is non-inferior to CT-P13 IV in terms of pharmacokinetics at Week 6.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female, aged at least 18 years old.  Diagnosis of inflammatory bowel disease according to the ECCO criteria for at least 3 months:  CD (Crohn's disease) UC (Ulcerative colitis) Patients had received conventional therapy for active UC (corticosteroids alone or in combination with thiopurines and 5-aminosalicylates) or CD (corticosteroids and/or immunomodulators) but had not responded despite an adequate course of therapy. Patient has active CD or UC with at least one objective sign of disease activity on biology, endoscopy or imaging. Initiation of infliximab CT-P13 as part of standard of care. Patient suffering from anal suppuration related to CD can be included. Person who has received full information about the organization of the research, who has not objected to his or her participation and to the use of his or her data. Person affiliated to or beneficiary of a social security plan.  Exclusion Criteria:  Combination therapy with an immunomodulator except for patients suffering from anal suppuration related to CD. Patient who has allergies to any of the excipients of infliximab CT-P13 or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product. Patient who had current or past history of chronic infection with hepatitis C or human immunodeficiency virus (HIV)-1 or -2 or current infection with hepatitis B. Patient who had acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug. Patients with a positive interferon-γ release assay (IGRA) or latent tuberculosis (TB) prior to initiation of biologic therapy. Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code: pregnant woman, parturient, or breastfeeding woman, minor person (non-emancipated), adult person under legal protection (any form of public guardianship), adult person incapable of giving consent. Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments
Status: Not yet recruiting

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers.

The main question it aims to answer is :

Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment?

The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients over 18 years old Patient with a diagnosis of a histologically proven solid malignant tumor with an indication for systemic treatment during initial treatment. CT/PET performed within 45 days before initiation of systemic treatment. Patient able to sign informed consent for participation in the study Patient affiliated to a social security system  Exclusion Criteria:  History of cancer in the five years preceding inclusion other than localized skin or cervical cancers. Patient with cancer not requiring systemic treatment. Pregnant women. Patient with a pace maker or defibrillator Patient deprived of liberty or benefiting from a legal protection measure - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Serum Magnesium Level and Pediatric Migraine
Status: Not yet recruiting

Aim: The purpose of this study is to compare serum magnesium levels between patients with migraine and a control group and to examine the relationship between the frequency and duration of attacks in patients with migraine and mean serum magnesium levels.

Material-Method: Patients diagnosed presenting to the Balıkesir University Medical Faculty pediatric neurology clinic between 01.09.2019 and 01.04.2023 and diagnosed with migraine were enrolled retrospectively. Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic in the same period as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin, hematocrit, platelet, glucose, calcium, magnesium, vitamin D, folate and ferritin levels) characteristics were recorded.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group.  Exclusion Criteria:  Patients and controls in whom Mg therapy was contraindicated (renal failure or nephrolithiasis), with non-migraine headaches, with substance/drug addiction (abuse), with psychiatric and/or chronic systemic diseases, and cases with histories of drug use (antidepressants, neuroleptics, tranquilizer group, antiepileptic medications (lithium and carbamazepine), using headache prophylaxis (beta blockers and calcium antagonists), and patients with deficient file data were excluded from the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 72 Months - MaximumAge: 18 Years - StdAgeList: Child, Adult - StudyPopulation: Patients diagnosed presenting to the Balıkesir University Medical Faculty pediatric neurology clinic, Türkiye, between 01.09.2019 and 01.04.2023 and diagnosed with migraine were included retrospectively. The study was approved by the institutional clinical research ethics committee (decision no. 2023/68 dated 10.05.2023).  Patients diagnosed with migraine were included as the study group and healthy children presenting to the pediatric neurology clinic at the same times were enrolled as the control group. The demographic characteristics (age, sex, and body mass index) of the patient group and their clinical (attack durations and frequencies, symptoms during attacks, and treatments) and laboratory (hemoglobin (Hb), hematocrit (Hct), platelet, glucose, calcium (Ca), magnesium (Mg), vitamin D, folate and ferritin levels) characteristics were recorded. - SamplingMethod: Non-Probability Sample
DivAirCity Social Health Survey
Status: Recruiting

To reduce stress among urban residents, the consortium members of the European Council Horizon 2020 research program DivAirCity install different stress reducing, noise reducing and air quality improving means in the five cities of the consortium. This study measures physiological and psychological stress and health factors before and after the implementation of the project (at intervention sites) and compares the change (improvement) to the change in comparable places where no means were installed (control site).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participants must live or work at or near the installation (intervention group) or control site (control group)  Exclusion Criteria:  none - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Residents of the five cities (18+ years of age) - SamplingMethod: Non-Probability Sample
Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients
Status: Not yet recruiting

Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. These bowel symptoms often remain prevalent, even at 12 months after RC treatment. Most assessment tools are however not capable of capturing the full range or therapeutic-related evolution of these bowel symptoms. Consequently, the aim is to develop a validated bowel diary for diagnosing and evaluation of all bowel symptoms.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures. At least 18 years of age at the time of signing the Informed Consent Form (ICF). Proficient in reading, comprehending, and conversing in Dutch . Patients diagnosed with a rectal tumour based on a pathology report.  Exclusion Criteria:  The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection. Experienced fecal incontinence prior to undergoing surgery. Are affected by neurological disorders affecting bowel function. Already underwent previous pelvic surgery, previous pelvic radiation or rectal surgery for non-cancer reasons. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients diagnosed with a rectal tumour based on a pathology report - SamplingMethod: Non-Probability Sample
Optimal Treatment of Acute Skeletal Muscle Injury
Status: Not yet recruiting

Acute muscle strain injuries occur both during sports, in leisure time activities and during manual occupation and represent a major clinical challenge and has societal economic costs. The recovery time is long and a substantial injury recurrence is observed. Despite current best evidence rehabilitation with early mechanical loading, a significant loss of muscle mass, fatty infiltration and formation of scar tissue is reported.

Animal models and human in vitro experiments suggest that inflammation is vital in the early period after an injury, however an inhibition of inflammatory processes is beneficial for healing.

We investigate here whether a pharmacological inhibition of inflammatory pathways in the 2nd week following a muscle strain injury will provide a better clinical outcome and an advantageous cellular profile than rehabilitative training alone would.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Sports-active individuals with an acute muscle train injury in either the hamstrings or calf muscle caused by an explosive movement (during sprinting, jumping etc) Age older than 18 years  Exclusion Criteria:  Lack of hypoechoic/ hyperechoic area on ultrasound Diabetes type I and II Connective tissue disorders, rheumatism or any other chronic disease affecting the musculoskeletal system Anticoagulant medication Needle phobia - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Evaluation of Kidney Damage Using NGAL Measurements
Status: Recruiting

The main objective of this study is to evaluate whether blood NGAL measurement provides superiority over sCr and BUN tests in early diagnosis for assessing renal function in patients undergoing robotic urological surgery.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  A total of 55 patients, with ASA scores 1-2-3, aged between 18 and 80 years, will be included in the study conducted at the Robotic Surgery operating room of Ankara City Hospital, Ministry of Health, Turkey.  Exclusion Criteria:  -1. Individuals who do not have the ability to read, understand, or sign the consent form.  2. Individuals with diagnosed renal disease. 3. Patients who do not wish to participate in the study. 4. Patients classified as ASA-3 or higher. - HealthyVolunteers: No - Gender: Male - GenderBased: Yes - GenderDescription: Participants were selected from male individuals as the evaluation was conducted on patients undergoing prostatectomy. - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: A total of 55 patients, with ASA scores 1-2-3, aged between 18 and 80 years, will be included in the study conducted at the Robotic Surgery operating room of Ankara City Hospital, Ministry of Health, Turkey. - SamplingMethod: Probability Sample
Using TMS to Understand Neural Processes of Social Motivation
Status: Not yet recruiting

The purpose of this study is to use transcranial magnetic stimulation (TMS) to better understand the neural circuits associated with social motivation.

Participant includes four study visits each that range from 1.5 - 3.0 hours in duration over approximately a one month period. The first study visit involves answering survey questions, a clinical interview, and computer tasks. The second study visit involves a magnetic resonance imaging (MRI) scan, computer tasks, and a brief TMS protocol. The second and third study visits involve a full session of TMS followed by an MRI scan and computer tasks.

Adults in the Auburn/Apelika area who avoid social situations, experience symptoms of depression or social anxiety, and are between 25 years old and 50 years old are eligible to participate.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  A diagnosis of Major Depressive Disorder OR a diagnosis of Social Anxiety Disorder (assessed/confirmed at screening visit). Scoring above clinical threshold on a measure of social avoidant behavior (assessed/confirmed at screening visit).  Exclusion Criteria:  Unstable medication regimen (i.e., changes in medication or dosage in past 3 months). Current or lifetime diagnosis of Bipolar Disorder. A diagnosis of substance use disorder within past 12 months. A diagnosis of psychotic-spectrum disorder such as Schizophrenia. Pregnancy or probable pregnancy. Medical illness or medical treatment that would preclude or inhibit study participation. Neurological disorder or prior neurosurgical procedure. History of seizures or head trauma. Metal implants or objects within body (e.g., pacemaker). - HealthyVolunteers: No - Gender: All - MinimumAge: 25 Years - MaximumAge: 50 Years - StdAgeList: Adult
The Effect of the Care Given to Hemodialysis Patients on Comfort Level and Complaints
Status: Not yet recruiting

Kolcaba's comfort theory is a theory used by nurses to increase the comfort of patients. There are limited studies determining that nursing care provided according to this theory contributes to the increase in patients' comfort levels in various patient groups. This study will be carried out in the hemodialysis center of a public hospital located in the city center of Bingöl. Patients in the intervention group receiving hemodialysis treatment will be given nursing care by the researcher for 12 sessions during the sessions in which the patient receives hemodialysis treatment. In order to provide nursing care, nursing diagnoses suitable for the patient group will be determined in advance and the care the patient needs will be given according to these diagnoses.. If necessary, the researcher will add additional diagnoses to the preliminary diagnosis form and provide care.

In this research, the individual nursing care needs of the researcher patient will be determined. Individualized caregiving is unique to this study. Individually provided care is expected to increase patient comfort and satisfaction. Increased comfort will help the patient cope more easily with the disease and hemodialysis treatment symptoms. In addition, the results of individual care provided can guide nurses in their care behaviors. By adding this research to the literature, the groundwork will be laid for studies that will provide individual care to patients. It is expected that the results of this research will guide the planning of the research and the provision of individualized care in all patient groups, especially patients receiving hemodialysis treatment.

Eligibility:
- EligibilityCriteria: Inclusion criteria:  Clinical diagnosis of chronic renal failure Receiving 3 sessions of hemodialysis treatment per week Over 18 years old Must be able to communicate  Exclusion Criteria:  Having a psychiatric illness - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Project Phakama: Testing Support Strategies to Empower Young Women on PrEP in South Africa
Status: Not yet recruiting

The goal of this trial is to understand which strategies work best to support pre-exposure prophylaxis (PrEP) use among female sex workers (FSW) and adolescent girls and youth women (AGYW) in uMgungundlovu, KwaZulu-Natal, South Africa. Participants will be randomly assigned to receive a combination of up to four support strategies encourage the participants in continuing to use PrEP. The four strategies being tested are: case management, food vouchers, peer support buddies, and community-based PrEP pick-up points. The intention of this trial is to determine which PrEP support strategy or bundle(s) of strategies best promote(s) long-term PrEP use, so that these services can be scaled up to other districts in South Africa.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Initiated PrEP within the past 48 hours by the TB HIV Care PrEP programme in uMgungundlovu through the female sex worker (FSW) or adolescent girls and young women (AGYW) PrEP programme teams  Exclusion Criteria:  Not eligible for PrEP Currently on PrEP, but initiated onto PrEP more than 48 hours previously Under 16 years of age if AGYW OR under 18 years of age if FSW - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - GenderBased: Yes - GenderDescription: Identifies as a cisgender woman (assigned female sex at birth and currently identifies as a woman). - MinimumAge: 16 Years - StdAgeList: Child, Adult, Older Adult
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
Status: Recruiting

This early phase I trial evaluates the feasibility and impact of a meditation headband system (MUSE-S) for breast cancer survivors. Anxiety and insomnia are among the most common distresses in breast cancer survivors during and after chemotherapy, in part due to the side effects of chemotherapy, fear of cancer coming back, progression of the cancer, and uncertainty of the future. These distresses impair patients' well-being and quality of life (QOL) in general, and their cancer treatment adherence and effectiveness in particular. Meditation has been demonstrated to be an effective management tool of stress and anxiety and is given the highest level of evidence (grade A) in the systematic review-based guidelines by the Society of Integrative Medicine. The portable, interactive, electroencephalographic (EEG) Muse headband guided meditation has been shown to improve fatigue, QOL, and stress in newly diagnosed breast cancer patients. The MUSE-S Headband System may decrease anxiety and insomnia among breast cancer survivors.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age between 18-80 Breast cancer first diagnosed with stage 1-4 breast cancer in the past 10 years Patients report experiencing anxiety and insomnia both rated > 3 on a 0-10 scale (with 0 indicating none) at the time of enrollment Patients on anti-anxiety/anti-depressant medication must be on stable dose for 1 month prior to study enrollment and must stay on that same dose throughout the trial Has smart phone or tablet Patient willing to use Google-based anonymous email account to sign up for MUSE Be willing to provide informed consent and complete all aspects of the study Have no contraindicating comorbid health condition which would interfere with the proper use of the Muse-S (trademark) system, as determined by the clinical investigators  Exclusion Criteria:  Pregnant or breastfeeding individuals Individuals who have used a regular mindfulness practice or received integrative medicine therapy, including acupuncture/acupressure, mindfulness or stress-reduction programs, massage, and/or energy therapies within the past 60 days Currently taking medication for insomnia An exclusionary unstable medical or mental health condition as determined by the patient's oncologist - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult